Journal article
Cliodhna Caffrey, Anna Leamy, Ellen O’Sullivan, I. Zabetakis, R. Lordan, C. Nasopoulou
Marine Drugs, 2023
Marine Drugs, 2023
Semantic Scholar
DOI
Cite
Cite
APA
Click to copy
Caffrey, C., Leamy, A., O’Sullivan, E., Zabetakis, I., Lordan, R., & Nasopoulou, C. (2023). Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids. Marine Drugs.
Chicago/Turabian
Click to copy
Caffrey, Cliodhna, Anna Leamy, Ellen O’Sullivan, I. Zabetakis, R. Lordan, and C. Nasopoulou. “Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids.” Marine Drugs (2023).
MLA
Click to copy
Caffrey, Cliodhna, et al. “Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids.” Marine Drugs, 2023.
BibTeX Click to copy
@article{cliodhna2023a,
title = {Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids},
year = {2023},
journal = {Marine Drugs},
author = {Caffrey, Cliodhna and Leamy, Anna and O’Sullivan, Ellen and Zabetakis, I. and Lordan, R. and Nasopoulou, C.}
}
Abstract
Cardiovascular diseases (CVD) remain the leading cause of death across the globe, hence, establishing strategies to counteract CVD are imperative to reduce mortality and the burden on health systems. Dietary modification is an effective primary prevention strategy against CVD. Research regarding dietary supplementation has become increasingly popular. This review focuses on the current in vivo, in vitro, and epidemiological studies associated with that of omega-3 polyunsaturated fatty acids (n-3 PUFAs) and polar lipids (PLs) and how they play a role against CVD. Furthermore, this review focuses on the results of several major clinical trials examining n-3 PUFAs regarding both primary and secondary prevention of CVD. Notably, we place a lens on the REDUCE-IT and STRENGTH trials. Finally, supplementation of PLs has recently been suggested as a potential alternative avenue for the reduction of CVD incidence versus neutral forms of n-3 PUFAs. However, the clinical evidence for this argument is currently rather limited. Therefore, we draw on the current literature to suggest future clinical trials for PL supplementation. We conclude that despite conflicting evidence, future human trials must be completed to confirm whether PL supplementation may be more effective than n-3 PUFA supplementation to reduce cardiovascular risk.
